Literature DB >> 12487809

Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

José M Benito1, Mariola López, Juan C Martín, Sara Lozano, Pilar Martínez, Juan González-Lahoz, Vincent Soriano.   

Abstract

The mechanism of CD4(+) T cell depletion seen in HIV infection is largely mediated by increased apoptosis of these cells. The benefit of protease inhibitor (PI)-based antiretroviral therapy to CD4(+) T cell recovery seems to involve more than its antiviral activity, and a direct antiapoptotic effect of PIs has been proposed to explain it. To test this hypothesis we have analyzed directly, ex vivo, the effects of two different highly active antiretroviral therapy (HAART) regimens on the levels of activation and apoptosis of T lymphocytes. A total of 126 subjects (43 receiving PIs, 35 receiving NNRTIs, 27 untreated HIV carriers, and 21 uninfected control subjects) was included in the study. Apoptosis was measured in blood lymphocytes by flow cytometry, using annexin V labeling. A broad panel of monoclonal antibodies was used to characterize the different CD4(+) and CD8(+) lymphocyte subsets. Apoptosis was significantly increased in HIV-untreated subjects, whereas apoptosis levels did not differ when comparing HIV-positive subjects undergoing HAART and uninfected control subjects. Likewise, markers of activation were elevated in HIV-positive untreated patients, and declined in subjects receiving treatment. However, activated-memory CD8(+) T cells remained significantly higher in treated patients with respect to uninfected control subjects. No differences in the level of apoptosis or in immune activation markers were recognized when comparing subjects receiving PIs and those receiving NNRTIs. Antiretroviral therapy reduces apoptosis of CD4(+) and CD8(+) lymphocytes to normal levels without differences when comparing subjects receiving PI and NNRTI triple combinations. Despite complete suppression of viral replication, activated memory CD8(+) T cells remain significantly elevated in subjects receiving HAART, suggesting the persistence of residual HIV replication. If PIs provide a positive effect on CD4(+) counts beyond an antiviral effect, mechanisms other than apoptosis should be involved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12487809     DOI: 10.1089/088922202320935456

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  14 in total

1.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

2.  Virome analysis of antiretroviral-treated HIV patients shows no correlation between T-cell activation and anelloviruses levels.

Authors:  Linlin Li; Xutao Deng; Antonio Charlys Da Costa; Roberta Bruhn; Steven G Deeks; Eric Delwart
Journal:  J Clin Virol       Date:  2015-10-08       Impact factor: 3.168

3.  Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants.

Authors:  Prem L Sharma; Himabindu Chunduri; Jasen Wise; Rondeen Mindley; David Rimland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

4.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

5.  Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Authors:  Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud
Journal:  AIDS Patient Care STDS       Date:  2008-07       Impact factor: 5.078

6.  Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation.

Authors:  J M Benito; M López; S Lozano; C Ballesteros; J González-Lahoz; V Soriano
Journal:  Clin Exp Immunol       Date:  2007-05-18       Impact factor: 4.330

7.  High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.

Authors:  Damalie Nakanjako; Isaac Ssewanyana; Harriet Mayanja-Kizza; Agnes Kiragga; Robert Colebunders; Yukari C Manabe; Rose Nabatanzi; Moses R Kamya; Huyen Cao
Journal:  BMC Infect Dis       Date:  2011-02-08       Impact factor: 3.090

8.  Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Authors:  Reena Rajasuriar; Maelenn Gouillou; Tim Spelman; Tim Read; Jennifer Hoy; Matthew Law; Paul U Cameron; Kathy Petoumenos; Sharon R Lewin
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

Review 9.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

10.  A single intravenous dose of prednisolone induces phosphatidylserine externalization, loss of surface marker expression and a 24-h net increase in human peripheral blood lymphocytes ex vivo.

Authors:  Martin Jetzek-Zader; Sonja Gudowius; Oliver Feyen; Markus Stevens; Peter Lipfert; Tim Niehues
Journal:  Rheumatol Int       Date:  2007-03-01       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.